BR112014026718A2 - variantes ctla-4 - Google Patents

variantes ctla-4

Info

Publication number
BR112014026718A2
BR112014026718A2 BR112014026718A BR112014026718A BR112014026718A2 BR 112014026718 A2 BR112014026718 A2 BR 112014026718A2 BR 112014026718 A BR112014026718 A BR 112014026718A BR 112014026718 A BR112014026718 A BR 112014026718A BR 112014026718 A2 BR112014026718 A2 BR 112014026718A2
Authority
BR
Brazil
Prior art keywords
ctla
variants
stability
monthly
cytotoxic
Prior art date
Application number
BR112014026718A
Other languages
English (en)
Other versions
BR112014026718B1 (pt
Inventor
Privezentzev Cyril
Moisan Jacques
Douthwaite Julie
Bowen Michael
Minter Ralph
Rust Steve
Original Assignee
Medimmune Ltd
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Medimmune Llc filed Critical Medimmune Ltd
Publication of BR112014026718A2 publication Critical patent/BR112014026718A2/pt
Publication of BR112014026718B1 publication Critical patent/BR112014026718B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425—Zeins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo "variantes ctla-4". variantes do antigênio 4 do linfócito t citotóxico (ctla-4), com elevada afinidade, atividade e estabilidade. formulações de variantes de ctla-4 em elevada concentração para a administração subcutânea ou intravenosa, por exemplo, em intervalos de dosagem mensais ou menos frequentes. utilização de variantes de ctla-4 no tratamento de artrite reumatoide e outras doenças inflamatórias. fusão de ctla-4 com igg fc tendo uma estabilidade melhorada e uma meia-vida in vivo mais prolongada. 22889140v1 1/1 22889140v1
BR112014026718-9A 2012-05-11 2013-03-11 polipeptídeo isolado de ctla-4, célula hospedeira, composição e uso de um polipeptídeo ctla-4 BR112014026718B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11
US61/645,686 2012-05-11
PCT/US2013/030179 WO2013169338A1 (en) 2012-05-11 2013-03-11 Ctla-4 variants

Publications (2)

Publication Number Publication Date
BR112014026718A2 true BR112014026718A2 (pt) 2017-07-18
BR112014026718B1 BR112014026718B1 (pt) 2021-05-18

Family

ID=49551120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026718-9A BR112014026718B1 (pt) 2012-05-11 2013-03-11 polipeptídeo isolado de ctla-4, célula hospedeira, composição e uso de um polipeptídeo ctla-4

Country Status (17)

Country Link
US (2) US9884902B2 (pt)
EP (2) EP3207938B1 (pt)
JP (1) JP6228971B2 (pt)
KR (1) KR102133060B1 (pt)
CN (2) CN107540742B (pt)
AU (1) AU2013260172B2 (pt)
BR (1) BR112014026718B1 (pt)
CA (1) CA2868748C (pt)
DK (1) DK3207938T3 (pt)
ES (1) ES2777778T3 (pt)
HK (1) HK1209644A1 (pt)
HU (1) HUE048925T2 (pt)
MX (1) MX355234B (pt)
PL (1) PL3207938T3 (pt)
RU (1) RU2671465C2 (pt)
SG (2) SG11201405968SA (pt)
WO (1) WO2013169338A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
HUE047077T2 (hu) * 2012-06-29 2020-04-28 Bristol Myers Squibb Co Eljárások glikoprotein aggregáció csökkentésére
WO2014138188A1 (en) * 2013-03-07 2014-09-12 The General Hospital Corporation Human ctla4 mutants and use thereof
EP3101035B1 (en) * 2014-01-28 2021-10-06 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR20180012260A (ko) 2015-04-17 2018-02-05 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
CN108137659B (zh) 2015-08-21 2021-11-26 汉阳大学校产学协力团 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
CN108513576A (zh) * 2015-09-14 2018-09-07 高山免疫科学股份有限公司 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
JP7058609B2 (ja) 2016-04-15 2022-04-22 アルパイン イミューン サイエンシズ インコーポレイテッド Ｉｃｏｓリガンドバリアント免疫調節タンパク質およびその使用
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
KR20200010294A (ko) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
MA50360A (fr) * 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
MA50404A (fr) 2017-10-18 2020-08-26 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
JP2022505045A (ja) * 2018-11-02 2022-01-14 ベイジン ブイディージェイバイオ カンパニー， リミテッド 修飾されたｃｔｌａ４およびその使用方法
WO2020210596A1 (en) * 2019-04-10 2020-10-15 University Of Kentucky Research Foundation Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use
AU2021205976A1 (en) * 2020-01-11 2022-07-07 Yale University Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with DNAse1 and/or DNAse1L3 deficiency
US12049488B2 (en) * 2020-04-06 2024-07-30 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
CA3234491A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CA3234496A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022414315A1 (en) * 2021-12-17 2024-07-25 Kashiv Biosciences, Llc An improved assay method for determining the potency of recombinant protein
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE170562T1 (de) 1991-06-27 1998-09-15 Bristol Myers Squibb Co Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997047732A2 (en) * 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
UA87432C2 (uk) * 2000-05-26 2009-07-27 Бристол-Майерс Сквибб Компани Розчинний мутантний ctla4 та його застосування
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP4784772B2 (ja) 2005-07-07 2011-10-05 東芝ライテック株式会社 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
PL2222697T3 (pl) 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosupresyjne polipeptydy i kwasy nukleinowe
ES2826894T3 (es) * 2010-02-19 2021-05-19 Xencor Inc Nuevas inmunoadhesinas CTLA4-IG
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants

Also Published As

Publication number Publication date
CN104302309A (zh) 2015-01-21
RU2671465C2 (ru) 2018-10-31
CN107540742B (zh) 2021-06-29
HK1209644A1 (en) 2016-04-08
BR112014026718B1 (pt) 2021-05-18
CN104302309B (zh) 2017-07-28
JP2015523328A (ja) 2015-08-13
SG10201609447XA (en) 2017-01-27
KR20150014443A (ko) 2015-02-06
EP3207938A2 (en) 2017-08-23
CA2868748A1 (en) 2013-11-14
US20150104450A1 (en) 2015-04-16
JP6228971B2 (ja) 2017-11-08
EP2863936A4 (en) 2016-10-05
HUE048925T2 (hu) 2020-09-28
AU2013260172B2 (en) 2017-11-23
MX2014013092A (es) 2015-03-03
AU2013260172A1 (en) 2014-10-23
EP3207938A3 (en) 2017-11-01
SG11201405968SA (en) 2014-11-27
US20180208639A1 (en) 2018-07-26
CN107540742A (zh) 2018-01-05
MX355234B (es) 2018-04-11
CA2868748C (en) 2022-07-26
KR102133060B1 (ko) 2020-07-10
EP2863936A1 (en) 2015-04-29
EP3207938B1 (en) 2019-12-25
DK3207938T3 (da) 2020-03-16
WO2013169338A1 (en) 2013-11-14
ES2777778T3 (es) 2020-08-06
US9884902B2 (en) 2018-02-06
RU2014150092A (ru) 2016-07-10
PL3207938T3 (pl) 2020-07-13

Similar Documents

Publication Publication Date Title
BR112014026718A2 (pt) variantes ctla-4
MX2013005341A (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
WO2018157171A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
EA200801570A1 (ru) Стабильные белковые препараты
Semerano et al. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
Kukushkin et al. Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
HRP20211197T1 (hr) Rekombinantni glikoproteini i njihova uporaba
CY1113683T1 (el) Συστημα συσκευασιας για φαρμακευτικες συνθεσεις και kit για ενδοφλεβια χορηγηση
TN2014000132A1 (en) Dosage regimen for an s1p receptor modulator or agonist
BR112017004590A2 (pt) métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l
BR112015013223A2 (pt) composição farmacêutica
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
Gouzien et al. Clozapine-induced parotitis: a case study
PH12017501005A1 (en) Injectable formulations of paracetamol
Ricklin et al. Preclinical development and in vivo evaluation of next-generation compstatin analogs with improved systemic profiles: a novel option for the treatment of paroxysmal nocturnal hemoglobinuria
Reilly Ask the doctor. I'm in my late 70s and have been getting about four cortisone shots a year for the past several years for the arthritis in my left knee. They really help with the pain, but I've heard that long-term, there could be bad side effects. Should I be worried?
Minford Protein-C
Lim et al. Analysis of Vancomycin Plasma Concentrations Following Initial Dosing in Critically Ill Patients
Pozzi Carbamazepine/risperidone interaction
Pentsova Renal failure, hyponatraemia, deep vein thrombosis: 3 case reports

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MEDIMMUNE LIMITED. (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2013, OBSERVADAS AS CONDICOES LEGAIS.